RE:RE:RE:RE:RE:RE:RE:Bullboard...Gorf79 wrote: Rumpl, I have no idea who Briacell is. It looks like you would like to settle on this company as your benchmark though. If I cared enough I’d list a hundred other biotechs that actually go up on good news. You do understand that concept right, it’s really sort of standard operating procedure for public companies... release good news competently = an increase in your share price, NOT a 35% Loss. Is that relationship that difficult to comprehend.
But hang on tight to your extreme outlier example, there are some here who will eat it up. Using other company’s failures for comparison has long been the M.O. here. God forbid posters compare the share price performance here to winners. That creates questions, and my goodness we can’t have those!
Suffice to say I have a higher expectation of those who hold a stewardship position in the public equities I invest in.
And please provide me some further detail on where I said management “sucked”?
Keep singing from Bencro’s song sheet.
Just for the record Briacell is a for Venture company that is in trials for breast cancer.
At one point I tried to convince their CEO to take a look at TLT and TLD1433 but they chose to go with Keytruda instead.
I had accumulated 30,000 shares at an average of 30 cents when in 2019 the new Chairman decided they would do a 1 for 300 consolidation (ouch). I also tried to talk him out of that but in January of 2020 they completed the consolidation with the share price at 4 cents. They then opened at $12 and actually ran up to the $25 area -- a double -- the 4 cents became 8 cents! But then as normal in many consolidations the share price began to drop. I took my 100 shares (30,000 divided by 300) and sold them at $19. Price sounds good but it was actually just over 6 cents per share compared to my original buy in of 30 cents. I do have problems getting SP's to go up.
The consolidation plan was to accomodate a move to the Nasdaq. They did that just over a year later i.e. February 2021. In addition they maintained the Venture listing and have since upgraded to the TSX. They currently are trading in the $9 Cdn range - so 3 cents compared to their pre-consolidation 2020 price of 4 cents. ($7.23 U.S.)
They also expanded their partnerships & trials as well and got together with Incyte's retifanlimab and epacadostat in addition to Merck's keytruda.
Needless to say with the very low share count after the 1 for 300 they have been able to do some financings.
Just a little history for Briacell.